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Arginase is an enzyme that catalyzes the formation of L-ornithine and 
urea from L-arginine. L-arginine is also a substrate for nitric oxide 
synthase (NOS), resulting in the formation of nitric oxide (NO) which is a 
key vasodilator. Not surprisingly, arginase inhibitors are being studied to 
treat various diseases, including hypertension, erectile dysfunction, 
atherosclerosis, wound healing and myocardial reperfusion injury. 
Recently, the use of virtual screening and docking to identify and 
characterize novel arginase inhibitors as potential therapeutics to treat 
leshmania infections has been reported in the literature. Hence, there is 
interest in the development of new and improved arginase inhibitors. Here, 
we describe the use of an iterative in silico and in vitro work-flow for 
identifying novel arginase inhibitors. The first in silico arm of the work-flow 
involves the use of library design, virtual screening, docking, and 
consensus scoring to identify predicted hit compounds. The in vitro arm 
involves rapid assaying of predicted hits in an optimized arginase assay. 
Confirmed hits are passed into the second in silico arm which involves 
ligand-based screening, docking, and consensus scoring. The crank is 
turned on the in silico – in vitro – in silico cycle until a promising candidate 
for hit-to-lead optimization has been identified. Preliminary results appear 
encouraging, providing hope that a novel arginase drug candidate will be 
identified and that our computational work-flow will prove useful on other 
targets.
Protein-Receptor
Virtual Libraries based 
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from Zinc Database
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criteria 
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Software 
Vega-ZZ
v Generates poses and ΔG’s
v Each virtual compound has ten modeled poses
v Sort out duplicates between the five different binding criteria
v Compare pose to crystal ligand pose
v Analyze distance of docked ligand and metal in enzyme 
v Look for hydrogen bonding interactions
v Analyze fit in binding pockets look for cavities in enzyme
v Look for acceptable pose buy compound test on in vitro assay
v Generate pharmacological hit  
v Rationally design virtual library based on Lipinski’s Rules
molecular weight, log P, and other criteria
v Test only compounds that can be purchased with the
selected compounds to be  tested on just the
target/enzyme
v When pharmaceutical hit is found it  can be drawn to find 
congeners for further optimization
J. Chem. Inf. Model., 2015, 55 (11), pp 2324–2337
v Top 5% of virtual 
compounds are 
summarized in excel 
sheet
v Each virtual compound 
10 different 
conformations
v Excel computes 
duplicates from the five 
different criteria that 
evaluates virtual 
docking studies
Medicinal Research Reviews 37(3) · November 2016
Figure 1 Arginase as part of the hepatic urea cycle. ASL, argininosuccinate 
lyase; ASS, argininosuccinate synthetase; CPS, carbamoyl phosphate 
synthetase; OTC, ornithine transcarbamoylase.
PNAS. 2005 Sept; 102(37): 13058–13063., Medicinal Research Reviews 37(3) · November 2016
Figure 2   Schematic representation of inhibitor bond to human arginase I.  
Direct H-bonds and mediated H-bonds are represented, respectively, with 
vertical (III) and horizontal (---) dotted lines.  For clarity, residues involved in 
manganese binding are presented in gray.
Proc Natl Acad Sci USA 2005;102 (37):13058-13063, Biochemistry 2009, 48(1):121-131, Medicinal Research Reviews 
37(3) · November 2016
vMutagenesis studies confirm water mediated H-bonding with Thr 
135, Asn 130, and Asp 183
v Other important residues Glu 227 and Hist 141 form H-bonds 
v Using physical properties for the ligands, multiple parameters for 
docking studies allows smaller more manageable libraries/data
v Biological assay/testing of the interesting compounds from docking 
studies to be evaluated  in vitro on the target enzyme
v Initial identification of the pharmaceutical hit optimize via virtual 
compounds
v Identification of the pharmacophore  
v Look for biological clues that will drive the synthetic chemistry
v Are there cavities in the enzyme that can be build into
v Find new hydrogen bonding interactions
v Fragment based drug design
v Generate synthetic schemes to generate congeners of the  
pharmaceutical hit
v Continue molecular modeling to support synthetic chemistry 
v Evaluate pharmacokinetics  ADMETable 1 Different parameters 
applied for the docking studies
Figure 4  Pose of both docked 
ligand and crystal structure of 
inhibitor (gold) from protein 
model with metal manganese 
(green)
v The urea cycle is an essential metabolic pathway for the removal of 
highly toxic ammonium ion form the body 
v Incyte paid 45 million for  small molecule arginase inhibitor
Figure 3 Pose of docked ligand 
showing the distance with the metal 
manganese (green) look for 
distances < 2.5 Å
Figure 5 Pose of docked malonic 
acid binding similar to NOHA 
(gold), metal manganese (green)
Figure 6  Pose of docked malonic 
acid fitting into the  active site grey 
hydrophobic areas
Figure 7  Pose of docked malonic 
acid fitting into the  active site 
showing potential cavities 
Figure 8  Active site with inhibitor malonic acid.  Showing the 
important amino acids and the distances to the important 
hydrogen bonding amino acids THR 135, ASN 130, ASP 183.
v Generate 
Docking 
studies with 
congeners of 
malonic acid 
v Build into the 
hydrogen 
bonding 
residues THR 
135, ASN 
130, ASP 183 
that are 6-8 Å  
away
v Virtual 
Congeners of 
known 
inhibitors
Malonic Acid
v Arginase is a trimeric binuclear manganese metalloenzyme that 
catalyzes the hydrolysis of L-arginase to form L-ornithine and urea
v Arginase I (322-residue) functions in the urea cycle and is located 
primarily in the cytoplasm of the liver 
v The second isozyme, Arginase II, has been implicated in the 
regulation of the arginine/ornithine concentrations in the cell it is 
located in mitochondria of several tissues in the body
v Early inhibitors centered on α-amino acids and were weak
v Arginase inhibitors can increase L-arginase concentrations and 
thereby enhance NO (nitric oxide) biosynthesis potential treatment  
for asthma and cardiovascular diseases
v Arginase I is significantly up-regulated and promotes tumor cell 
growth in breast cancer, colorectal cancer, and lung cancer
v Infectious diseases Helicobacter, Mycobacterium, Salmonella, 
Trypanosomia, Leishmania, Candida species all encode their own 
arginase and modulate its activity/expression during infection
v Many of the arginase inhibitors have poor pharmacokinetics and low 
selectivity arginase I vs. arginase II
Br J Pharmacol. 2009 Oct; 158(3): 638–651., Comp.Biochem.Physiol. Vol. 114 B No. 1 pp. 107-132, 1996
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